NI200900183A - Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer. - Google Patents
Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer.Info
- Publication number
- NI200900183A NI200900183A NI200900183A NI200900183A NI200900183A NI 200900183 A NI200900183 A NI 200900183A NI 200900183 A NI200900183 A NI 200900183A NI 200900183 A NI200900183 A NI 200900183A NI 200900183 A NI200900183 A NI 200900183A
- Authority
- NI
- Nicaragua
- Prior art keywords
- pyrid
- pi3k
- pyrimidine
- cancer
- treatment
- Prior art date
Links
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 108091007960 PI3Ks Proteins 0.000 title 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Radiology & Medical Imaging (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91116007P | 2007-04-11 | 2007-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI200900183A true NI200900183A (es) | 2010-10-05 |
Family
ID=39642739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI200900183A NI200900183A (es) | 2007-04-11 | 2009-10-09 | Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer. |
Country Status (25)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006065703A1 (en) * | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| NZ608667A (en) * | 2005-10-07 | 2014-08-29 | Exelixis Inc | N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| HRP20130902T1 (hr) * | 2005-10-07 | 2013-11-08 | Exelixis Inc. | PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa |
| CA2658725A1 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| MY146420A (en) | 2006-09-15 | 2012-08-15 | Pfizer Prod Inc | Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors |
| DK2139484T3 (da) | 2007-04-10 | 2013-10-21 | Exelixis Inc | Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa |
| AU2008239655B2 (en) * | 2007-04-11 | 2013-06-20 | Exelixis, Inc. | Pyrido (2, 3-d) pyrimidin-7-one compounds as inhibitors of PI3k-alpha for the treatment of cancer |
| TW201018685A (en) * | 2008-09-30 | 2010-05-16 | Exelixis Inc | Pyridopyrimidinone inhibitors of PI3Kα and mTOR |
| NZ600954A (en) * | 2009-12-22 | 2013-11-29 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | |
| WO2011100319A1 (en) | 2010-02-09 | 2011-08-18 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors |
| CA2812089C (en) | 2010-09-14 | 2020-02-18 | Exelixis Inc. | Inhibitors of pi3k-delta and methods of their use and manufacture |
| WO2013056067A1 (en) * | 2011-10-13 | 2013-04-18 | Exelixis, Inc. | Compounds for use in the treatment of basal cell carcinoma |
| KR20140096083A (ko) | 2011-11-01 | 2014-08-04 | 엑셀리시스, 인코포레이티드 | 림프증식성 악성종양의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제로서 ｎ（3｛［（3｛［2클로로5（메톡시）페닐］아미노｝퀴녹살린2일）아미노］설포닐｝페닐）2메틸알라닌아미드 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2937284A (en) * | 1958-05-01 | 1960-05-17 | Burroughs Wellcome Co | 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method |
| IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| US7019002B2 (en) * | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
| US20080255162A1 (en) * | 2004-05-04 | 2008-10-16 | Warner-Lambert Company Llc | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents |
| HRP20130902T1 (hr) * | 2005-10-07 | 2013-11-08 | Exelixis Inc. | PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa |
| US8247408B2 (en) * | 2005-10-07 | 2012-08-21 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer |
| CA2658725A1 (en) * | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| MY146420A (en) * | 2006-09-15 | 2012-08-15 | Pfizer Prod Inc | Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors |
-
2008
- 2008-04-11 AU AU2008239596A patent/AU2008239596B2/en not_active Ceased
- 2008-04-11 WO PCT/US2008/004807 patent/WO2008127712A1/en not_active Ceased
- 2008-04-11 MX MX2009010815A patent/MX2009010815A/es active IP Right Grant
- 2008-04-11 ES ES08742864T patent/ES2425068T3/es active Active
- 2008-04-11 EA EA200970936A patent/EA018964B1/ru not_active IP Right Cessation
- 2008-04-11 NZ NZ579945A patent/NZ579945A/en not_active IP Right Cessation
- 2008-04-11 MY MYPI20094194 patent/MY150747A/en unknown
- 2008-04-11 KR KR1020097023146A patent/KR20090130104A/ko not_active Ceased
- 2008-04-11 JP JP2010503085A patent/JP2010523681A/ja active Pending
- 2008-04-11 CA CA002683820A patent/CA2683820A1/en not_active Abandoned
- 2008-04-11 BR BRPI0810175-2A2A patent/BRPI0810175A2/pt not_active IP Right Cessation
- 2008-04-11 US US12/595,233 patent/US20100209340A1/en not_active Abandoned
- 2008-04-11 UA UAA200911451A patent/UA101315C2/ru unknown
- 2008-04-11 EP EP08742864.5A patent/EP2142544B8/en active Active
- 2008-04-11 CN CN200880018758A patent/CN101711249A/zh active Pending
-
2009
- 2009-09-23 ZA ZA200906648A patent/ZA200906648B/xx unknown
- 2009-09-24 TN TNP2009000389A patent/TN2009000389A1/fr unknown
- 2009-09-29 IL IL201209A patent/IL201209A0/en unknown
- 2009-10-09 DO DO2009000242A patent/DOP2009000242A/es unknown
- 2009-10-09 SV SV2009003389A patent/SV2009003389A/es not_active Application Discontinuation
- 2009-10-09 NI NI200900183A patent/NI200900183A/es unknown
- 2009-10-30 MA MA32314A patent/MA31336B1/fr unknown
- 2009-11-09 CR CR11098A patent/CR11098A/es unknown
- 2009-11-09 EC EC2009009722A patent/ECSP099722A/es unknown
- 2009-11-09 CO CO09126919A patent/CO6241119A2/es not_active Application Discontinuation
-
2013
- 2013-01-03 US US13/694,772 patent/US20130343988A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CR11098A (es) | 2010-01-27 |
| ECSP099722A (es) | 2009-12-28 |
| MY150747A (en) | 2014-02-28 |
| UA101315C2 (ru) | 2013-03-25 |
| TN2009000389A1 (en) | 2010-12-31 |
| ZA200906648B (en) | 2010-04-28 |
| AU2008239596B2 (en) | 2013-08-15 |
| ES2425068T3 (es) | 2013-10-11 |
| NZ579945A (en) | 2012-05-25 |
| EP2142544B8 (en) | 2013-07-03 |
| DOP2009000242A (es) | 2010-04-30 |
| BRPI0810175A2 (pt) | 2014-12-30 |
| CN101711249A (zh) | 2010-05-19 |
| KR20090130104A (ko) | 2009-12-17 |
| EA200970936A1 (ru) | 2010-02-26 |
| SV2009003389A (es) | 2010-04-27 |
| WO2008127712A1 (en) | 2008-10-23 |
| EP2142544B1 (en) | 2013-05-22 |
| AU2008239596A1 (en) | 2008-10-23 |
| EA018964B1 (ru) | 2013-12-30 |
| US20130343988A1 (en) | 2013-12-26 |
| CA2683820A1 (en) | 2008-10-23 |
| JP2010523681A (ja) | 2010-07-15 |
| MA31336B1 (fr) | 2010-04-01 |
| EP2142544A1 (en) | 2010-01-13 |
| US20100209340A1 (en) | 2010-08-19 |
| IL201209A0 (en) | 2010-05-31 |
| CO6241119A2 (es) | 2011-01-20 |
| MX2009010815A (es) | 2009-10-29 |
| HK1139941A1 (en) | 2010-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI200900183A (es) | Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer. | |
| ECSP109856A (es) | Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842 | |
| CR20120130A (es) | Compuestos de benzoxepina inhibidores de la pi3k y métodos de uso | |
| UY31254A1 (es) | Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones | |
| UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
| UY32296A (es) | Nuevos compuestos | |
| NI201000004A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
| UY31127A1 (es) | Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841 | |
| UY31918A (es) | Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento | |
| NI201000003A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
| SV2010003598A (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa | |
| DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
| UY29781A1 (es) | Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos | |
| CU20110078A7 (es) | Compuestos de carbazol | |
| UY33075A (es) | Derivados de ciclohexano y usos de los mismos | |
| SV2010003472A (es) | Compuestos de pirazol | |
| DOP2013000221A (es) | INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA | |
| ECSP10010415A (es) | Compuestos novedosos que son inhibidores de erk | |
| ECSP11011526A (es) | Aril-piridinas como inhibidoras de sintasa de aldosterona | |
| DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
| ECSP099751A (es) | Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazo[4,5-b]piridin-5-amina y su uso para el tratamiento del cáncer | |
| UY31048A1 (es) | Nuevos compuestos de pirimidina y usos de los mismos | |
| ECSP13012596A (es) | Proceso de elaboración para derivados de pirimidina | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| BR112012029647A2 (pt) | novos derivados de pirimidinas |